Direct emissions
38,468
tCO2e
H
Hikma Pharmaceuticals Public Limited Company
Explore carbon emissions data for Hikma Pharmaceuticals Public Limited Company. Mycelium helps you review reported emissions, disclosure status, Scope 1, Scope 2 and Scope 3 data, climate targets and sustainability information in one company profile.
This profile brings together available carbon emissions data for Hikma Pharmaceuticals Public Limited Company, including reported figures, modelled estimates, disclosure documents and sustainability indicators, so you can review its emissions and compare its performance against similar companies. Read how we source and check this data.
Emissions
Carbon emissions
Total yearly emissions across all scopes
1,057,980 tCO2e (Market Based)
Scope 1
tCO2e
38,468
Scope 2 (Market Based)
tCO2e
81,804
Scope 3 total
tCO2e
937,708
Scope 3 reported
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
Provenance
Emissions
Factors
424,820
kgCO2e / £M
Supplier specific emission factors (kgCO2e / £M)
Modelled
Reported
Scope 1 + 2
Direct + purchased energy
48,294
48,294
Upstream
+ upstream Scope 3
374,808
373,691
Total
+ all Scope 3
424,820
393,902
Which figure should I use?
Use Modelled. It is the most complete view: any categories the company hasn't disclosed are filled with industry-typical estimates, so a transparent company isn't unfairly penalised against one that simply hasn't reported.
Reported counts only emissions the company has filed itself. A blank or low Reported cell doesn't mean those emissions don't exist, just that the company hasn't disclosed them.
When Reported sits close to Modelled, that is a positive signal. The company has disclosed most of its salient emissions and there's little gap for the model to fill. Even then, Modelled is the right figure to use for a like-for-like comparison across companies.
Sustainability
Snapshot
Based on reported data, retrieved with AI
- Hikma Pharmaceuticals Public Limited Company reported 1,057,980 tCO₂e in 2024.
- Scope 3 accounted for 89% of emissions.
- Reported across 9 of 15 GHG Protocol Scope 3 categories.
- Scope 2 reported under the market based methodology.
According to available emissions disclosures, Hikma Pharmaceuticals Public Limited Company reported total yearly emissions of 1,057,980 tCO₂e in 2024. Scope 3 emissions accounted for 89% of reported output, indicating supply chain activity, purchased goods and services, business travel, and wider operational dependencies were the most significant contributors to the company's carbon footprint.
The company achieved a Mycelium Score of 3.5, placing it below average for its sector for sustainability performance, and received a transparency score of 79.3, meaning they share solid detail across the main emissions areas.
Total Emissions across all scopes
1,057,980 tCO2e (Market Based)
Scope 1 emissions
Direct emissions from sources the company owns or controls, such as fuel use, facilities and vehicles.
Scope 2 emissions
Indirect emissions from purchased energy, including electricity, heating and cooling.
Location based
87,237
tCO2eMarket based
81,804
tCO2eScope 3 emissions
Wider value chain emissions across the 15 GHG Protocol categories, from purchased goods and business travel to investments, where reported.
Cat 1
Purchased goods & services
681,235
tCO2eCat 2
Capital goods
46,580
tCO2eCat 3
Fuel & energy related activities
31,683
tCO2eCat 4
Upstream transportation & distribution
32,084
tCO2eCat 5
Waste generated in operations
2,079
tCO2eCat 6
Business travel
8,312
tCO2eCat 7
Employee commuting
8,401
tCO2eCat 8
Upstream leased assets
2,783
tCO2eCat 9
Downstream transportation & distribution
2,783
tCO2eCat 10
Processing of sold products
2,783
tCO2eCat 11
Use of sold products
42,089
tCO2eCat 12
End-of-life treatment of sold products
8,247
tCO2eCat 13
Downstream leased assets
2,783
tCO2eCat 14
Franchises
2,783
tCO2eCat 15
Investments
63,082
tCO2e6 values were derived via Mycelium's normalisation process rather than reported by the company. Cells marked “–” were not disclosed.
Contact Info
Website
www.hikma.comAddress
1
New Burlington Place
London
London
Greater London (Westminster)
W1S 2HR
Country
United Kingdom
Phone
+44 20 7399 2760Browse carbon emissions data by industry
Jump straight into the sectors users explore most, or view all industries.
How scoring works
How the Mycelium Score is calculated
The Mycelium Score is out of 10. Up to 6.5 points reflect carbon intensity vs sector peers (emissions normalised against revenue). The remaining 3.5 reflect data quality: third-party verified, profile claimed by the company, and full disclosure across all reporting categories.
A higher score means lower carbon intensity than sector peers, backed by data that's third-party verified, claimed by the company, and fully disclosed. Hikma Pharmaceuticals Public Limited Company's score sits at the top of this page and in the score panel.
How the Transparency Score is calculated
The Transparency Score measures how much of a company's key emissions data is publicly disclosed, graded from A (very high) down to F (very low). Crucially, it weights each gap by how material that bucket is for the company's industry, so an undisclosed category where the bulk of emissions sit hurts far more than a minor one.
For Hikma Pharmaceuticals Public Limited Company, the single biggest gap is Investments (Scope 3 Category 15). Mycelium estimates it accounts for around 6% of the company's total footprint, typically the largest source of emissions for a Services company, yet it hasn't been disclosed. Leaving a bucket this large unreported is what's holding the transparency score down.
In total, roughly 6% of Hikma Pharmaceuticals Public Limited Company's estimated emissions sit in categories it hasn't reported. Disclosing these would be the fastest way to raise the transparency score.
Read the full scoring methodology
Our white paper covers exactly how the Mycelium Score and Transparency Score are calculated, including the normalisation process and what earns a 10/10.
Download the white paper (PDF)
Hikma Pharmaceuticals Public Limited Company carbon emissions FAQs
What are Hikma Pharmaceuticals Public Limited Company's carbon emissions?
In its 2024 reporting year, Hikma Pharmaceuticals Public Limited Company disclosed total emissions of 1,057,980 tCO2e across all scopes. Scope 3 accounted for the largest share, around 89% of the total.
Does Hikma Pharmaceuticals Public Limited Company report Scope 1, Scope 2 and Scope 3 emissions?
For 2024, Hikma Pharmaceuticals Public Limited Company's available disclosure covers Scope 1 (38,468 tCO2e), Scope 2 (81,804 tCO2e), Scope 3 across 9 of the 15 GHG Protocol categories. Figures not reported by the company are shown as modelled estimates and labelled as such.
How transparent is Hikma Pharmaceuticals Public Limited Company's emissions reporting?
Hikma Pharmaceuticals Public Limited Company has a Mycelium transparency score of 79.3 out of 100. The score weights each emissions category by how material it is for the company's industry, so it reflects whether the disclosures that matter most have been made.
Is Hikma Pharmaceuticals Public Limited Company sustainable?
Mycelium measures sustainability through carbon emissions data rather than giving a yes or no verdict. Hikma Pharmaceuticals Public Limited Company has a Mycelium Score of 3.5 out of 10, which reflects its emissions intensity against sector peers together with how transparent and well-verified its reporting is. The emissions figures, disclosure documents and climate targets on this page give the fuller picture.
Is Hikma Pharmaceuticals Public Limited Company environmentally friendly?
Carbon emissions are one measurable part of environmental impact, and the part Mycelium tracks. Hikma Pharmaceuticals Public Limited Company disclosed 1,057,980 tCO2e for 2024, and its Mycelium Score of 3.5 out of 10 shows how that performance compares with similar companies in its sector.
Learn more about our methodology and where this data comes from.
